1210 Christina B. Felsen et al

7. Madden GR, Weinstein RA, Sifri CD. Diagnostic stewardship for healthcareassociated infections: opportunities and challenges to safely reduce test use. Infect Control Hosp Epidemiol 2018;39:214-218.

8. Lilly CM, Landry KE, Sood RN, et al. Prevalence and test characteristics of National Health Safety Network ventilator-associated events. Crit Care Med

Innovative methods to summarize nursing home antibiotic data

Christina B. Felsen MPH¹, Grant R. Barney BS² and Ghinwa K. Dumyati MD^{1,3}

¹Center for Community Health and Prevention, University of Rochester Medical Center, Rochester, New York, ²University at Albany, School of Public Health, Albany, New York and ³Infectious Diseases Division, University of Rochester Medical Center, Rochester, New York

To the Editor—Kabbani et al¹ published an interesting report on the utility of pharmacy dispensing data to measure antibiotic days of therapy (DOT) and antibiotic starts in nursing homes. Their data analysis was limited by a lack of resident identifiers, which led to a reliance on the number of antibiotic transactions as a proxy for starts. The authors state that this is likely an overestimate because antibiotic courses in nursing homes are often dispensed incrementally. As part of a 5-year, quality improvement study conducted in several nursing homes in Rochester, New York, we developed a methodology for calculating antibiotic starts, inferring missing data and providing data feedback to help nursing homes monitor their antibiotic use over time. The primary goals of the project were to reduce C. difficile infections (CDI) and to implement antibiotic stewardship programs (ASPs) via a hospital-nursing home partnership.

We worked with pharmacists at 7 in-house and commercial dispensing pharmacies to obtain antibiotic data that included (1) drug name (2) date and quantity dispensed (3) directions for use (4) duration (5) resident location and unique identifier, and (6) ordering provider. In some cases, obtaining the data required sending the pharmacy a template spreadsheet to illustrate the data needed and/or having a conversation with the pharmacist to discuss the importance of the requested data elements. Data were often received on paper or in a format that was not conducive to manipulation so extensive manual data entry was conducted. We also performed substantial data cleaning to remove topical, ophthalmic, and otic agents; antivirals and antifungals; antibiotics given for noninfectious reasons (eg, gastroparesis); and prescriptions for emergency-box replacement. Drug names were standardized using their generic equivalents; indications were categorized into common syndromes including urinary tract and lower respiratory infections. Time variables (year, quarter, and month) were added to track data over time. If not included in the original data, DOT, defined as the aggregated days a resident received an antibiotic, was calculated manually using the quantity dispensed and directions for use. Using SAS version 9.3 software (SAS Institute, Cary NC), we collapsed observations of the same antibiotic prescribed to the same resident within 4 days of the preceding prescription to calculate antibiotic starts and

Author for correspondence: Christina Felsen, MPH, Center for Community Health and Prevention, 46 Prince Street, Rochester, NY. E-mail: Christina_Felsen@urmc.rochester.edu Cite this article: Felsen CB, Barney GR, and Dumyati GK. (2019). Innovative methods to

summarize nursing home antibiotic data. Infection Control & Hospital Epidemiology, 40: 1210-1211, https://doi.org/10.1017/ice.2019.226

© 2019 by The Society for Healthcare Epidemiology of America. All rights reserved.

duration and to infer the indication if it had not been carried over from the original observation.

From these data, we generated several measures of antibiotic use including (1) total DOT rate; (2) DOT rate by the most common antibiotics and indications; (3) DOT rate by the number of residents and unit; (4) antibiotic starts; and (5) length of treatment. Each metric has several pros and cons. 1,2 The specific summary measures we found useful are summarized in Table 1. In our experience, nursing homes are most familiar with antibiotic starts and number of residents treated. Although the DOT rate is useful to monitor the facility-wide antibiotic burden, it is a less tangible measure and can be easily skewed by residents on chronic, prophylactic antibiotics.² Other metrics that we found to be especially valuable to nursing homes are usage by unit to account for differences in resident populations and comparative DOT rates from long-term care units across several nursing homes to encourage friendly competition. We created a data dashboard to summarize these metrics and shared the dashboard with nursing home ASP teams at face-to-face, quarterly meetings. During these meetings, we also provided coaching on how to interpret the data and make it actionable. Examples of nursing home interventions based on the summarized antibiotic data include (1) determining where documentation breakdowns occurred in a nursing home with a large number of prescriptions missing indication; (2) monitoring drug selection, specifically fluoroquinolone use to reduce CDI risk^{3,4} for common infections such as urinary tract infections; and (3) comparing length of treatment to treatment durations suggested by established guidelines.⁵

The main limitation of our analysis was the inability to verify that dispensed antibiotics were actually administered. However, in our experience, dispensing data are sufficient to guide nursing homes in the development of ASP interventions. Unlike the limitations faced by Kabbani et al, collaboration with dispensing pharmacists allowed us to obtain data that included fields like resident identifier and location as well as antibiotic indication, allowing for more robust analyses. The in-depth evaluation of nursing home antibiotic data that we conducted was made possible by our hospital-based team's expertise in stewardship and infectious diseases and our dedicated time to clean and summarize the data. We believe that it is important to share the lessons we have learned from this process because visualizing trends in a nursing home's antibiotic data is the best way to identify areas for improvement and monitor progress over time. However, our methodology may not be possible for nursing home staff that have competing priorities and fewer resources. Therefore, we created a tool in collaboration with the Atlantic Quality Innovation Network/IPRO to help nursing homes monitor their antibiotic use. The tool requires manual data entry but automatically summarizes data by

Table 1. Description of Possible Antibiotic Summary Measures

Measure	Calculation	How It Was Used	Limitations
Total use	$\frac{\sum \textit{DOT}}{\textit{Resident days during interval}}*1000$	Measures total antibiotic burdenTracks use over time	• Separate units may use antibiotics differently (eg, ventilator/rehab units).
Use by unit	$\frac{\sum \textit{DOT by specific unit}}{\textit{Resident days on unit during interval}}*1000$	Compares how units use antibiotics differently Can limit comparative data across NHs to similar unit types (eg, long-term care only)	
Most common indications and agents by DOT	 Sum total DOT for each indication or agent Rank from most to least common 	 Identifies which infections and agents contribute the greatest burden Helps target specific interventions (UTI, quinolone use, etc) 	(ie, prophylactic and suppressive use)
Most common indications by number of residents	Sum number of residents treated for each indication Rank from most to least common	Identifies which infections are the most commonly treated Highlights how a fewer number of residents receiving long-term therapies may bias DOT measures	Resident identifiers may not be available.
Drug selection by indication	 Filter all drugs dispensed for a particular indication (eg, UTI) Sum DOT for each individual agent Visually helpful to graph as a stacked column for each period of interest (eg, month or quarter) 	Helps track adherence to treatment guidelines (eg, limiting quinolone use for UTI) over time	
Starts and LOT	Collapse prescriptions into starts Summarize treatment duration	Helps track adherence to treatment guidelines	Requires resident identifiers and indications Time-consuming without programming software
Proportion of unknown indications	$\frac{\sum Unknown X}{\sum X} * 100$		
	 Sum the total prescriptions, DOT, or starts that do not have an indication Divide by total prescriptions, DOT, or starts 		
Use by provider	All of the above measures may be applied to specific providers.	Provides specific provider feedback; spurs competition	Not all dispensing data have a field for prescribers, or the prescriber may default to the resident's attending provider.

Note. DOT, days of therapy; LOT, length of treatment; NH, nursing home; UTI, urinary tract infection.

antibiotic, indication, unit, and prescriber. It is available on our website (http://www.rochesterpatientsafety.com/index.cfm? Page=For Nursing Homes) along with our guide to cleaning antibiotic data and our SAS code for collapsing data into antibiotic starts. In summary, we hope that our experiences and methods will be useful to the nursing home community in monitoring and improving antibiotic usage.

Author ORCIDs. Christina Felsen, (b) 0000-0002-7677-6708

Acknowledgments. We thank David Johnson from the Atlantic Quality Innovation Network/IPRO for his role in the development of our antibiotic tracking tool. Additionally, we thank the staff and providers at all participating nursing homes and pharmacies.

Financial support. This project was supported by a grant from the New York State Department of Health.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

- Kabbani S, Palms DL, Bartoces M, et al. Potential utility of pharmacy data to measure antibiotic use in nursing homes. Infect Control Hosp Epidemiol 2019;40:819–820.
- Mylotte JM. Antimicrobial stewardship in long-term care: metrics and risk adjustment. J Am Med Dir Assoc 2016;17:672 e13-8.
- Piacenti FJ, Leuthner KD. Antimicrobial stewardship and Clostridium difficile-associated diarrhea. J Pharm Pract 2013;26:506–513.
- Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of *Clostridium difficile* infection. Clin Infect Dis 2011;53:42–48.
- Stone ND, Ashraf MS, Calder J, et al. Surveillance definitions of infections in long-term care facilities: revisiting the McGeer criteria. *Infect Control Hosp Epidemiol* 2012;33:965–977.